GT 007 - GRIT Biotechnology
Alternative Names: GT-007 - GRIT BiotechnologyLatest Information Update: 01 Dec 2023
At a glance
- Originator GRIT Biotechnology
- Class Antineoplastics; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 12 Sep 2023 Early research in Haematological malignancies in China (Parenteral) prior to September 2023 (GRIT Biotechnology pipeline, September 2023)